316 related articles for article (PubMed ID: 2157984)
1. New antifungal agents for the systemic mycoses.
Ringel SM
Mycopathologia; 1990 Feb; 109(2):75-87. PubMed ID: 2157984
[TBL] [Abstract][Full Text] [Related]
2. Azole antifungal agents: emphasis on new triazoles.
Saag MS; Dismukes WE
Antimicrob Agents Chemother; 1988 Jan; 32(1):1-8. PubMed ID: 2831809
[TBL] [Abstract][Full Text] [Related]
3. The triazole antifungal agents: a review of itraconazole and fluconazole.
Bailey EM; Krakovsky DJ; Rybak MJ
Pharmacotherapy; 1990; 10(2):146-53. PubMed ID: 2161523
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses.
Grant SM; Clissold SP
Drugs; 1989 Mar; 37(3):310-44. PubMed ID: 2540949
[TBL] [Abstract][Full Text] [Related]
5. Azole antifungal drugs: old and new.
Dismukes WE
Ann Intern Med; 1988 Aug; 109(3):177-9. PubMed ID: 2839058
[No Abstract] [Full Text] [Related]
6. Azole antifungal agents.
Bodey GP
Clin Infect Dis; 1992 Mar; 14 Suppl 1():S161-9. PubMed ID: 1314105
[TBL] [Abstract][Full Text] [Related]
7. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
Van Cutsem J
Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
[TBL] [Abstract][Full Text] [Related]
8. Oral azole drugs as systemic antifungal therapy.
Como JA; Dismukes WE
N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the treatment of systemic fungal infections.
Walsh TJ
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
[TBL] [Abstract][Full Text] [Related]
10. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.
Tucker RM; Denning DW; Hanson LH; Rinaldi MG; Graybill JR; Sharkey PK; Pappagianis D; Stevens DA
Clin Infect Dis; 1992 Jan; 14(1):165-74. PubMed ID: 1315160
[TBL] [Abstract][Full Text] [Related]
11. Treatment of systemic fungal infections: recent progress and current problems.
Walsh TJ; Pizzo A
Eur J Clin Microbiol Infect Dis; 1988 Aug; 7(4):460-75. PubMed ID: 2846299
[TBL] [Abstract][Full Text] [Related]
12. Opportunistic fungal infections in patients with acquired immune deficiency syndrome.
Viviani MA
Chemotherapy; 1992; 38 Suppl 1():35-42. PubMed ID: 1319314
[TBL] [Abstract][Full Text] [Related]
13. New antifungal agents.
Graybill JR
Eur J Clin Microbiol Infect Dis; 1989 May; 8(5):402-12. PubMed ID: 2546775
[TBL] [Abstract][Full Text] [Related]
14. Antifungal therapy: potential interactions with other classes of drugs.
Bickers DR
J Am Acad Dermatol; 1994 Sep; 31(3 Pt 2):S87-90. PubMed ID: 8077516
[TBL] [Abstract][Full Text] [Related]
15. [Importance of the new triazoles in antifungal therapy].
Durmaz B
Mikrobiyol Bul; 1991 Jan; 25(1):118-23. PubMed ID: 1652677
[TBL] [Abstract][Full Text] [Related]
16. Antifungal drugs.
Cross JT; Hickerson SL; Yamauchi T
Pediatr Rev; 1995 Apr; 16(4):123-9. PubMed ID: 7731906
[No Abstract] [Full Text] [Related]
17. Itraconazole and fluconazole: new drugs for deep fungal infection.
Warnock DW
J Antimicrob Chemother; 1989 Sep; 24(3):275-7. PubMed ID: 2553654
[No Abstract] [Full Text] [Related]
18. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Goa KL; Barradell LB
Drugs; 1995 Oct; 50(4):658-90. PubMed ID: 8536553
[TBL] [Abstract][Full Text] [Related]
19. Use of azoles for systemic antifungal therapy.
Kauffman CA; Carver PL
Adv Pharmacol; 1997; 39():143-89. PubMed ID: 9160115
[No Abstract] [Full Text] [Related]
20. [In-vitro and in-vivo activity of itraconazole].
Van Cutsem J
Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
